NASDAQ, TSX: NVCN VANCOUVER, March 21, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the year ended December 31, 2017...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Feb. 12, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present at the LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14th...
Read MoreParticipating Hospitals in Germany Now Eligible to Negotiate Reimbursement for Reducer Procedure NASDAQ, TSX: NVCN VANCOUVER, Feb. 1, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies, today announced that the "Institut...
Read MoreRecognized Multinational Senior Executive Poised to Drive Commercialization and Clinical Advances NASDAQ, TSX: NVCN VANCOUVER, Jan. 22, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq, TSX: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Jan. 18, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq, TSX: NVCN) today reported its Neovasc Reducer™ ("Reducer") was featured in a "live case" broadcast to more than 800 participants at the Kardiologie Symposium 2018 held in Berlin, Germany. The successful live case was...
Read More- 10 new implants performed in the past 60 days - NASDAQ, TSX: NVCN VANCOUVER, Jan. 8, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today provided an update on its clinical program for the Tiara™ ("Tiara") valve, a self-expanding mitral bioprosthesis for...
Read MoreVANCOUVER, Jan. 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX:NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid...
Read More- Clinical updates for both Reducer™ and Tiara™ also presented at premier event - NASDAQ, TSX: NVCN VANCOUVER, Dec. 6, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported its Neovasc Reducer™ ("Reducer") medical device was featured in a "live case"...
Read More